Le Lézard19 小时
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with ...
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September ...
Ipsen Pharma: Iqirvo (elafibranor) data shows efficacy and safety for up to 3 years in ...
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 202 ...